NEWS

Press Releases

May 19, 2020

Dyne Therapeutics Accelerates Programs in Facioscapulohumeral Muscular Dystrophy (FSHD) with Exclusive Licensing of Technologies to Target Genetic Basis of FSHD and Expanded Scientific Advisory Board

May 12, 2020

Dyne Therapeutics Demonstrates FORCETM Platform’s Potential to Deliver Potent Exon-Skipping Molecules Directly to Muscle to Treat Duchenne Muscular Dystrophy

May 11, 2020

Dyne Therapeutics Announces Appointment of Debra Feldman as Vice President, Head of Regulatory

April 23, 2020

Dyne Therapeutics Appoints David Lubner to Board of Directors

March 31, 2020

Dyne Therapeutics Announces Equity Investment from CureDuchenne Ventures to Support Pioneering Approach to Restoring Muscle Health in DMD

February 06, 2020

Dyne Therapeutics Expands Leadership Team with Key Hires

January 13, 2020

Dyne Therapeutics Announces Appointment of Molly White as Vice President, Medical Communications and Advocacy

Stay connected

Follow us on Twitter and LinkedIn.

Email: info@dyne-tx.com